GLP-1 Weight-Loss Drugs for Teens: What Is Actually Approved
This page exists because several sites blur adult and adolescent GLP-1 facts together, or get the trial numbers and drug names wrong. Below is what is actually FDA-approved, what the trial data actually shows, and where the real open questions are.
What is actually FDA-approved for adolescents
Wegovy (semaglutide) - approved December 23, 2022, for patients 12 years and olderwith obesity, defined as a BMI at or above the 95th percentile for age and sex on CDC growth charts. The FDA's indication has no upper age cutoff written into it - it simply covers 12-and-up, with adults 18+ additionally falling under the separate adult indication. Dosing and titration are the same schedule used in adults (0.25 mg building to a 1.7 mg or 2.4 mg weekly maintenance dose).
Saxenda (liraglutide) - approved December 4, 2020, for adolescents specifically ages 12-17, with body weight above 60 kg (132 lbs) and a BMI corresponding to the adult ≥30 threshold (a numeric cutoff, not a percentile - a real difference from Wegovy's criteria). It was the first FDA-approved obesity therapy for adolescents in over a decade at the time.
Zepbound (tirzepatide) and Mounjaro- not approved for adolescent weight loss. A pediatric obesity trial for tirzepatide (SURMOUNT-ADOLESCENTS) is active with no FDA filing or public results yet. Mounjaro (the same molecule, marketed for diabetes) did gain an FDA pediatric approval in December 2025 for patients 10 and older - but that approval is for type 2 diabetes glycemic control only, at a lower maximum dose (10 mg/week vs. the adult 15 mg/week ceiling), and has no bearing on Zepbound's weight-loss indication.
Ozempic - no pediatric or adolescent approval of any kind as of this writing.
The actual STEP TEENS trial numbers
Wegovy's adolescent approval rests on STEP TEENS, a 68-week trial of 201 adolescents (ages 12 to under 18). It reported two distinct results that are frequently conflated in secondary coverage:
| Metric (week 68) | Semaglutide | Placebo |
|---|---|---|
| BMI change (primary endpoint) | -16.1% | +0.6% |
| Body weight change (secondary) | -14.7% | +2.7% |
The two numbers differ because BMI accounts for height changes during adolescent growth and body weight does not - both are correctly reported figures, just different metrics. Gastrointestinal side effects were more common on semaglutide (62% vs. 42% on placebo), and gallstones occurred in 4% of the semaglutide group vs. none on placebo.
The AAP guideline, and two controversies worth knowing about
The American Academy of Pediatrics' January 2023 obesity guideline recommends pediatricians offer weight-loss medication to patients 12+ with obesity as an adjunct to lifestyle and behavioral treatment - not a first-line replacement for it, and generally after behavioral treatment alone has not been enough.
Eating-disorder screening concern (2023): the Academy for Eating Disorders and National Eating Disorders Association publicly raised concern that the guideline under-addressed eating-disorder screening and could reinforce weight stigma. The AAP said it would develop screening resources jointly with both groups.
Industry-funding disclosure finding (2025):a BMJ-published analysis reported that more than a third of the guideline's authors had undisclosed financial ties to GLP-1 manufacturers, and that GLP-1 drugmakers made an estimated $1.9-2.6 million in payments to the AAP itself from 2012-2024. The AAP has said corporate funding is a small share of its revenue and is not used in policy development, but has not made its conflict-of-interest review process public. This is a legitimate, separately reported finding - not a claim that the underlying clinical guidance is wrong, but a real transparency question about how it was produced.
What is genuinely still unknown
Growth, bone density, and puberty: STEP TEENS ran 68 weeks - long enough to support approval, not long enough to observe multi-year effects on growth or bone development. Independent pediatric researchers not affiliated with the trial have flagged this as a real open question, not a resolved one.
Stopping the medication:adolescent-specific data on regain speed after discontinuation is very limited. Most of what circulates about "what happens when you stop" is adult data extrapolated to teenagers, not a dedicated adolescent study - treat any specific adolescent regain timeline you see elsewhere with skepticism unless it cites STEP TEENS' own follow-up data directly.
Psychiatric safety - a more reassuring update: in January 2026 the FDA requested removal of the suicidal-ideation/behavior warning from Wegovy, Saxenda, and Zepbound labels, based on a meta-analysis of 91 trials (nearly 108,000 participants) that found no elevated risk. A September 2025 JAMA Pediatrics meta-analysis specific to youth (18 trials, 1,402 participants ages 6-17) reached the same conclusion.
Insurance and cost
Adult coverage on a plan does not automatically extend to an adolescent prescription. Insurers that do cover obesity treatment (UnitedHealthcare and Aetna both publish adolescent criteria) generally require the 95th-percentile BMI threshold rather than the adult numeric cutoff, and some - Aetna's policy is a documented example - also require 6 months of a supervised weight-management program first. Plans that exclude weight-management drugs entirely exclude them for every age, not just adolescents.
On Medicaid, federal EPSDT rules can require coverage for enrollees under 21 even after a state cuts adult coverage - Pennsylvania and California both ended adult Medicaid GLP-1 coverage effective January 1, 2026 while keeping it available to enrollees under 21. Mississippi remains the clearest example of a state explicitly covering GLP-1s for Medicaid enrollees 12 and older, a policy in place since 2023, though actual uptake has stayed low (roughly 2% of eligible enrollees).
NovoCare's Wegovy $25 copay card applies to an on-label adolescent prescription exactly as it does to an adult one - the published terms carry no age-based exclusion, only the standard rule against use by anyone on Medicaid or another government program. Without insurance, NovoCare's direct cash-pay price is $349/month, the same price posted for adult patients.
Telehealth will not prescribe to a minor
Every general adult telehealth platform this site covers for GLP-1 prescriptions - Ro, Found, LifeMD, and Noom - sets a minimum age of 18 for weight-loss services, with no exception. Found's terms are the most explicit: they reject even a parent or guardian's consent on a minor's behalf. Hims will prescribe to 13-17-year-olds only for acne treatment, not weight loss. In practice, an adolescent GLP-1 prescription comes from an in-person pediatrician, an adolescent-medicine specialist, or a smaller telehealth service built specifically around pediatric care - not from the mainstream direct-to-consumer weight-loss brands.
Frequently asked questions
Is Wegovy FDA-approved for teenagers?
Yes, with a precise scope worth getting right. The FDA approved Wegovy (semaglutide) on December 23, 2022 for patients 12 years and older with obesity, defined as a BMI at or above the 95th percentile for age and sex on CDC growth charts - not the flat 27+/30+ BMI number used for adults. Coverage often gets shortened to "ages 12-17" in headlines, but the FDA's actual indication language has no upper-age cutoff written into it - patients 18 and up simply fall under the pre-existing adult indication instead.
Is Zepbound or Mounjaro approved for teenagers?
No - and this is a common point of confusion. Zepbound (tirzepatide, the weight-loss brand) has no adolescent or pediatric FDA approval as of mid-2026. A pediatric obesity trial (SURMOUNT-ADOLESCENTS, ages 12-17) is active but had not reported results or led to an FDA filing as of this writing. Separately, Mounjaro - the same molecule, tirzepatide, marketed for type 2 diabetes - did receive an FDA pediatric approval (patients 10 and older) in December 2025, but strictly for diabetes glycemic control, not weight loss, and at a lower maximum dose (10 mg/week vs. the adult 15 mg/week ceiling). Do not read a Mounjaro pediatric diabetes approval as meaning Zepbound is approved for teen weight loss - it is not.
How much weight did teens actually lose in the Wegovy trial?
The trial that supported FDA approval, STEP TEENS (201 adolescents, 68 weeks), reported two distinct numbers that are easy to conflate. The primary endpoint - BMI - fell 16.1% on semaglutide vs. a 0.6% increase on placebo. Body weight itself, a secondary measure, fell 14.7% vs. a 2.7% increase on placebo. Both numbers are real; they are simply different metrics (BMI accounts for height changes during adolescent growth, body weight does not), and a source citing "16.1% weight loss" is technically citing the BMI figure.
What did the American Academy of Pediatrics say about GLP-1s for kids?
The AAP's January 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity recommends that pediatricians offer weight-loss pharmacotherapy to patients 12 and older with obesity as an adjunct to lifestyle and behavioral treatment - not as a first-line replacement for it, and only when behavioral treatment alone has not been sufficient. Two controversies followed the guideline itself and are worth knowing about: eating-disorder specialists (including the Academy for Eating Disorders and National Eating Disorders Association) publicly raised concern in 2023 that the guideline under-addressed eating-disorder screening; and a 2025 BMJ-published analysis found more than a third of the guideline's authors had undisclosed financial ties to GLP-1 manufacturers, with roughly $1.9-2.6 million in manufacturer payments to the AAP itself from 2012-2024. The AAP has defended its review process; the analysis is a legitimate part of the record either way.
What are the long-term safety unknowns specific to teenagers?
The honest answer is that long-term data does not exist yet. STEP TEENS ran 68 weeks - long enough to support FDA approval, not long enough to observe multi-year effects on growth, bone density, or puberty, which several independent pediatric researchers (not affiliated with the trial) have flagged as open questions rather than settled ones. Adolescent-specific data on what happens after stopping the drug (regain speed, re-titration) is also very limited - most of what is cited for "coming off a GLP-1" is adult data extrapolated downward, not a dedicated adolescent study. On the more reassuring side, the FDA requested removal of the suicidal-ideation/behavior warning from Wegovy's, Saxenda's, and Zepbound's labels in January 2026, based on a meta-analysis of 91 trials covering nearly 108,000 participants that found no elevated psychiatric risk - and a September 2025 JAMA Pediatrics meta-analysis specific to youth (18 trials, 1,402 participants ages 6-17) reached the same no-elevated-risk conclusion.
Will insurance cover a GLP-1 for my teenager?
It depends entirely on plan design, and coverage is not automatic just because an adult on the same plan is covered. Major commercial insurers that cover adult obesity treatment (UnitedHealthcare, Aetna, among others) generally extend prior-authorization approval to patients 12+ using the 95th-percentile BMI threshold, and some layer on an additional requirement - Aetna's policy, for example, requires 6 months of documented participation in a comprehensive weight-management program first. Other plans exclude weight-management drugs from coverage entirely regardless of age, which affects adolescents and adults identically. On Medicaid, federal EPSDT rules require coverage of medically necessary treatment for enrollees under 21 in some circumstances even after a state has cut adult coverage - Pennsylvania and California both cut adult Medicaid GLP-1 coverage effective January 1, 2026, while keeping it available to enrollees under 21 under EPSDT. Mississippi remains the most visible example of a state explicitly covering GLP-1s for Medicaid enrollees 12 and older since 2023, though real-world uptake has stayed low (about 2% of eligible enrollees). NovoCare's Wegovy $25 copay card applies to an on-label adolescent prescription the same way it applies to an adult one - there is no separate age-based term in the card's official rules, though it excludes anyone on Medicaid or another government program, exactly as it does for adults.
Can I get a GLP-1 prescription for my teenager through telehealth?
Not through the general direct-to-consumer platforms this site covers for adults. Ro, Found, LifeMD, and Noom all state a minimum age of 18 for weight-loss GLP-1 services, with no exception; Found's terms explicitly reject even a parent or guardian's consent on a minor's behalf. Hims allows prescribing to 13-17-year-olds only for acne treatment, not weight loss. A GLP-1 prescription for a 12-17-year-old, in practice, comes from an in-person pediatrician or adolescent-medicine specialist, or from a telehealth platform built specifically around pediatric care (a few smaller, specialty pediatric telehealth services now offer this) - not from the mainstream adult weight-loss telehealth brands.
Sources
- Novo Nordisk press releases on Wegovy (Dec 23, 2022) and Saxenda (Dec 4, 2020) adolescent approvals; FDA-approved prescribing information for both products.
- Weghuber D, et al. "Once-Weekly Semaglutide in Adolescents with Obesity." N Engl J Med 2022;387(24):2245-2257 (STEP TEENS).
- Hampl SE, et al. "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity." Pediatrics 2023;151(2):e2022060640.
- BMJ-published industry-funding analysis of the AAP guideline (reported by STAT News, July 2025, and Undark, September 2025).
- UnitedHealthcare and Aetna prior-authorization policy documents for Wegovy/Saxenda, adolescent criteria sections.
- KFF Health News reporting on Mississippi Medicaid GLP-1 coverage for enrollees 12+.
- FDA drug safety communication (January 2026) on removal of the suicidal ideation/behavior warning from GLP-1 labels.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.